// App-Quantinova.ai

: A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

Researchers

Presenter

  • Ian W. Flinn

Principal Investigators

  • Nirav N. Shah

  • Didier Blaise

  • Javier Briones

  • Leyla Shune

  • Nicolas Boissel

  • Attilio Bondanza

  • Darlene Lu

  • Xu Zhu

  • Boris Engels

  • Jennifer L Brogdon

  • Jennifer Mataraza

  • Jaclyn Davis

  • Anne Laure Marchal

  • Luisa Mariconti

  • Michele Moschetta

  • Laure Moutouh-de Parseval

  • Pere Barba

  • Michael Dickinson

Medical Centers

  • UNIVERSITY OF KANSAS MEDICAL CENTER, KANSAS CITY, KS

  • Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Vienna General Hospital - Medical University of Vienna, Vienna, Austria

  • Hematology Department, Hospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain

  • St-Louis Hospital, APHP, Adolescents and Young Adults Hematology Department, Paris, France

  • Peter MacCallum Cancer Centre and Royal Melbourne Hospital and the University of Melbourne, Melbourne, Australia

  • Sarah Cannon Research Institute, Nashville, TN

  • Medical College of Wisconsin, Milwaukee, WI

  • Department of Hematology, Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Novartis Institutes for BioMedical Research, Basel, Switzerland

  • Novartis Institutes for BioMedical Research, East Hanover, NJ

  • Département d'hématologie, Programme de transplantation et de thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille University, Institut Paoli Calmettes, Marseille, France

  • Novartis Institutes for BioMedical Research, Cambridge, MA

Locations

  • United States

  • Austria

  • Spain

  • Switzerland

  • France

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Multicenteric

  • Dose Escalation

  • Cohort

  • First-In-Human

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved